Anti-inflammatory effects of inhaled corticosteroids in chronic obstructive pulmonary disease: similarities and differences to asthma

Bibliography

• JEFFERY PK: Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir: Grit. Care Med. (2001)164(10 Part 2):S28–S38.
   Google Scholar
• GINA: Global initiative for asthma. Global Strategy for Asthma Management and Prevention. (2004).
   Google Scholar
• MURRAY CJL, LOPEZ AD: Alternative visions of the future: projecting mortality and disability. In: The global burden of disease. Murray CJ et al. (Eds) Harvard University Press, Harvard, USA (1996):361–375.
   Google Scholar
• SNIDER GL: Defining chronic obstructive pulmonary disease. In: Chronic Obstructive Pulmonary Disease. Calverley P et al. (Eds) Chapman and Hall, London, UK (1995):1–16.
   Google Scholar
• CALVERLEY PM: Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am. 1. Respir: Crit. Care Med. (2000) 161(2 Part 1):341-342 (Discussion 344).
   Google Scholar
• BARNES PJ: Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. I Respir: Crit. Care Med. (2000) 161(2 Part 1):342-344 (Discussion 344).
   Google Scholar
• GOLD: Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. (2003) 22(1):1–2.
   PubMed Web of Science ®Google Scholar
• STEURER-STEY C, BACHMANN LM, STEURER J, TRAMER MR: Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest (2004) 126(5):1645–1655.
   PubMed Web of Science ®Google Scholar
• JEFFERY PK, WARDLAW AJ, NELSON FC, COLLINS JV, KAY AB: Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am. Rev Respir: Dis. (1989) 140(6):1745–1753.
   PubMedGoogle Scholar
• BOUSQUET J, JEFFERY PK, BUSSE WW, JOHNSON M, VIGNOLA AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. I Respir: Grit. Care Med. (2000) 161(5):1720–1745.
   PubMed Web of Science ®Google Scholar
• RABE KF, MUNOZ NM, VITA AJ et al.: Contraction of human bronchial smooth muscle caused by activated human eosinophils. Am. J. Physic'. (1994) 267(3 Part 1):L326–L334.
   Google Scholar
• COLLINS DS, DUPUIS R, GLEICH GJ et al: Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. Am. Rev Respir: Dis. (1993) 147(3):677–683.
   PubMed Web of Science ®Google Scholar
• LEFF AR: Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes. The case for the eosinophil. Chest (1994)106(4):1202–1208.
   PubMed Web of Science ®Google Scholar
• ROBINSON DS: Cytokines 3: cytokines in asthma. Thorax (2003) 48:845–853.
   Google Scholar
• KIPS JC: Cytokines in asthma. Eur. Respir. Suppl. (2001) 34:24s–33s.
   Google Scholar
• BRIGHTLING CE, BRADDING P, SYMON FA et al.: Mast-cell infiltration of airway smooth muscle in asthma. N Engl. I Med. (2002) 346(22):1699–1705.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY TC, ANSARI TW, BARNES NC, JEFFERY PK: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8' T lymphocytes with FEVI. Am. I Respir: Crit. Care Med. (1997)155 (3):852–857.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of the predominance of the CD8, cell phenotype in bronchial biopsies (large airways) and of a negative association between these cells and MI of predicted in COPD.
   Google Scholar
• HOGG JC, CHU F, UTOKAPARCH S et al.: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl. I Med. (2004) 350(26):2645–2653.
   PubMed Web of Science ®Google Scholar
• ••Demonstrating an increasing accumulationof T and B cells in small airways from surgically removed lung tissue in subjects with increasing severity of COPD.
   Google Scholar
• KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. I Respir. Grit. Care Med. (1996) 153(2):530–534.
   PubMed Web of Science ®Google Scholar
• •Results from induced sputum indicate that the cytokines TNF-a and especially IL-8 are involved in the inflammation in COPD as compared with asthma.
   Google Scholar
• WOOLHOUSE IS, BAYLEY DL, STOCKLEY RA: Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of a(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax (2002)57(8):709–714.
   PubMed Web of Science ®Google Scholar
• CHRYSOFAKIS G, TZANAKIS N, KYRIAKOY D et al.: Perform expression and cytotoxic activity of sputum CD8' lymphocytes in patients with COPD. Chest (2004) 125(1):71–76.
   PubMed Web of Science ®Google Scholar
• STANESCU D, SANNA A, VERITER C et al: Airways obstruction, chronic expectoration, and rapid decline of FEVI in smokers are associated with increased levels of sputum neutrophils. Thorax (1996) 51(3):267–271.
   PubMed Web of Science ®Google Scholar
• DE BOER WI, VAN SCHADEWIJK A, SONT JK et al.: Transforming growth factor 131 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. I Respir. Grit. Care Med. (1998) 158(6):1951–1957.
   PubMed Web of Science ®Google Scholar
• DI STEFANO A, CARAMORI G, CAPELLI A et al.: STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur. Respir: 1 (2004) 24(1):78–85.
   Google Scholar
• SAETTA M, TURATO G, MAESTRELLI P, MAPP CE, FABBRI LM: Cellular and structural bases of chronic obstructive pulmonary disease. Am. I Respir. Grit. Care Med. (2001) 163(6):1304–1309.
   PubMed Web of Science ®Google Scholar
• LANG MR, FIAUX GW, GILLOOLY M et al.: Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax (1994) 49(4):319–326.
   PubMed Web of Science ®Google Scholar
• JEFFERY PK: Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin. Exp. Allergy (1999) 29\(Suppl. 2):14–26.
   Google Scholar
• TURATO G, ZUIN R, MINIATI M et al: Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am. I Respir: Crit. Care Med. (2002) 166(1):105–110.
   PubMed Web of Science ®Google Scholar
• DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy (2001) 31(6):893–902.
   PubMed Web of Science ®Google Scholar
• DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. I
   Google Scholar
• •• Respir Grit. Care Med. (1998)158(4):1277–1285.
   Google Scholar
• RETAMALES I, ELLIOTT WM, MESHI B et al.: Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am. J. Respir Crit. Care Med. (2001) 164(3):469–473.
   PubMed Web of Science ®Google Scholar
• DI STEFANO A, CARAMORI G, RICCIARDOLO FL etal.: Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. Clin. Exp. Allergy (2004) 34(8):1156–1167.
   Google Scholar
• JATAKANON A, UASUF C, MAZIAK W et al.: Neutrophilic inflammation in severe persistent asthma. Altai. Respir. Crit. Care Med. (1999) 160(5 Part 1):1532–1539.
   Google Scholar
• WENZEL SE, SZEFLER SJ, LEUNG DY et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Respir Grit. Care Med. (1997)156(3 Part 1):737–743.
   Google Scholar
• RODRIGUEZ-ROISIN R: Toward a consensus definition for COPD exacerbations. Chest (2000) 117(5 Suppl. 2):3985–4015.
   Google Scholar
• •The results of a workshop to discuss a focused, operational consensus defmition for COPD exacerbations.
   Google Scholar
• YING S, DURHAM SR, CORRIGAN CJ, HAMID Q, KAY AB: Phenotype of cells expressing mRNA for T2-type (interleukin 4 and interleukin 5) and T1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am. J. Respir Cell Mol. Biol. (1995) 12(5):477–487.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, YING S, CORRIGAN C et al.: Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am. Respir. Cell Mol. Biol. (1997) 16(1):1–8.
   PubMed Web of Science ®Google Scholar
• YING S, ROBINSON DS, MENG Q et al.: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. Immunol (1997) 27(12):3507–3516.
   Google Scholar
• LACOSTE JY, BOUSQUET J, CHANEZ P etal.: Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. I Allergy Clin. Immunol (1993) 92(4):537–548.
   Google Scholar
• ZHU J, MAJUMDAR S, QIU Y et al: Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(÷) cells. Am. J. Respir. Crit. Care Med. (2001) 164(12):2220–2228.
   Google Scholar
• ••Application of the molecular technique ofin situ hybridisation to localise and count cells expressing genes that regulate inflammation in chronic bronchitis.
   Google Scholar
• MULLEN JB, WRIGHT JL, WIGGS BR, PARE PD, HOGG JC: Reassessment of inflammation of airways in chronic bronchitis. BE Med. J. (Clin. Res. Ed.) (1985) 291(6504):1235–1239.
   PubMed Web of Science ®Google Scholar
• SAETTA M, DI STEFANO A, MAESTRELLI P et al: Airway eosinophilia in chronic bronchitis during exacerbations. Am. I Respir. Crit. Care Med. (1994) 150(6 Part 1):1646–1652.
   Google Scholar
• •Results indicating that in mild COPD exacerbations are associated with increases In airway eosinophils.
   Google Scholar
• ZHU J, QIU YS, MAJUMDAR S et al: Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am. .1 Respir. Crit. Care Med. (2001) 164(1):109–116.
   Google Scholar
• ••Data that sheds light on the mechanism oftissue recruitment of eosinophils in exacerbations of bronchitis in COPD.
   Google Scholar
• BHOWMIK A, SEEMUNGAL TA, SAPSFORD RJ, WEDZICHA JA: Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax (2000) 55(2):114–120.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the association betweensputum cytokines IL-6 and -8 and exacerbation frequency.
   Google Scholar
• SETHI S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest (2000) 117(5 Suppl. 2):380S–385S.
   Google Scholar
• LLOYD CM, DELANEY T, NGUYEN T etal.: CC chemokine receptor (CCR)3/ eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte Type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. (2000) 191(2):265–274.
   Google Scholar
• HADIDA F, VIEILLARD V, MOLLET L et al.: Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. .1 Immunol (1999) 163(3):1105–1109.
   Google Scholar
• KIM JJ, NOTTINGHAM LK, SIN JI et al: CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. Chu. Invest. (1998) 102(6):1112–1124.
   PubMed Web of Science ®Google Scholar
• JEFFERY P: Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease. In: Chronic Obstructive Pulmonary Disease. Chadwick D, Goode JA (Eds) (2001) JA Wiley & Sons, Chichester, UK:149–168.
   Google Scholar
• MURPHY TF, SETHI S: Bacterial infection in chronic obstructive pulmonary disease. Am. Rev Respir Dis. (1992) 146(4):1067–1083.
   PubMed Web of Science ®Google Scholar
• QIU Y, ZHU J, BANDI V et al: Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am. I Respir Grit. Care Med. (2003) 168(8):968–975.
   PubMed Web of Science ®Google Scholar
• ••Evidence from bronchial biopsies of theroles of CXCL8, CXCR1, CXCL5 and CXCR2 in severe exacerbations of COPD.
   Google Scholar
• SUR S, CROTTY TB, KEPHART GM et al.: Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. (1993) 148(3):713–719.
   Google Scholar
• AARON SD, ANGEL JB, LUNAU M et al.: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. I Respir Grit. Care Med. (2001) 163(2):349–355.
   PubMed Web of Science ®Google Scholar
• FAHY JV, KIM KW, LIU J, BOUSHEY HA: Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. I Allergy Clin. Immunol (1995) 95(4):843–852.
   PubMed Web of Science ®Google Scholar
• LAMBLIN C, GOSSET P, TILLIE-LEBLOND I etal.: Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am. I Respir. Crit. Care Med. (1998) 157(2):394–402.
   Google Scholar
• ORDONEZ CL, SHAUGHNESSY TE, MATTHAY MA, FAHY JV: Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am. Respir Crit. Care Med. (2000)161(4 Part 1):1185–1190.
   Google Scholar
• BARNES PJ, PEDERSEN S, BUSSE W: Efficacy and safety of inhaled corticosteroids: new developments. Am. Respic Grit. Care Med. (1998)157(3 Suppl. 2):S1–S53.
   Google Scholar
• SCHWIEBERT LM, BECK LA, STELLATO C et al.: Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J. Allergy Clin. Immunol (1996) 97(1 Part 2):143–152.
   Google Scholar
• LAITINEN LA, LAITINEN A, HAAHTELA T: A comparative study of the effects of an inhaled corticosteroid, budesonide, and a 02-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. j. Allergy Clin. Immunol (1992) 90(1):32–42.
   PubMed Web of Science ®Google Scholar
• DJUKANOVIC R, WILSON JW, BRITTEN KM et al.: Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev Respic Dis. (1992) 145(3):669–674.
   PubMed Web of Science ®Google Scholar
• FAUL JL, LEONARD CT, BURKE CM, TORMEY VJ, POULTER LW: Fluticasone propionate induced alterations to lung function and the immunopathology of asthma over time. Thorax (1998) 53(9):753–761.
   PubMed Web of Science ®Google Scholar
• WANG JH, DEVALIA JL, SAPSFORD RJ, DAVIES RJ: Effect of corticosteroids on release of RANTES and sICAM-1 from cultured human bronchial epithelial cells, induced by TNF-a. Eur. Respir. 1 (1997) 10(4):834–840.
   Google Scholar
• •An in vitro study of the effects and mechanism of corticosteroid treatment in reducing airway inflammation.
   Google Scholar
• MacFARLANE: BDP prevents the rise in epithelial RANTES after allergen challenge. Am. I Respic Grit. Care Med. (2000) 161:A834.
   Google Scholar
• KHARITONOV SA, DONNELLY LE, MONTUSCHI P et al: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax (2002) 57(10):889–896.
   PubMed Web of Science ®Google Scholar
• KETCHELL RI, JENSEN MW, LUMLEY P et al.: Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. I Allergy Clin. Immunol (2002)110(4):603–606.
   PubMed Web of Science ®Google Scholar
• BARNES PJ, ITO K, ADCOCK IM: Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet (2004)363(9410):731–733.
   PubMed Web of Science ®Google Scholar
• PAREDI P, KHARITONOV SA, BARNES PJ: Analysis of expired air for oxidation products. Am. I Respic Crk Care Med. (2002) 166(12 Part 2):S31–S37.
   Google Scholar
• ••Review of the measurement of exhaledgases as a means of detecting and monitoring cytokine-mediated Inflammation and oxidant stress in the airways, and of assessing the efficacy of treatment.
   Google Scholar
• MONTUSCHI P, COLLINS JV, CIABATTONI G et al: Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. I Respir. Grit. Care Med. (2000) 162(3 Part 1):1175–1177.
   Google Scholar
• MATTHEWS JG, ITO K, BARNES PJ, ADCOCK IM: Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J. Allergy Immunol (2004) 113(6):1100–1108.
   PubMed Web of Science ®Google Scholar
• DAAKA Y, LUTTRELL LM, LEFKOWITZ RJ: Switching of the coupling of the 02-adrenergic receptor to different G proteins by protein kinase A. Nature (1997) 390(6655):88–91.
   PubMed Web of Science ®Google Scholar
• EICKELBERG 0, ROTH M, LORX R et al: Ligand-independent activation of the glucocorticoid receptor by 02-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. I Biol. Chem. (1999) 274(2):1005–1010.
   Web of Science ®Google Scholar
• ••Evidence for a mechanism that improvesanti-inflammatory response to glucocorticoids, with 02-adrenergic receptor agonists.
   Google Scholar
• ROTH M, RUDIGER J, BIHL M: The 0-agonist formoterol activates the glucocorticoid receptor in vivo. Eur. Respir. J. (2000) 16(437s).
   PubMed Web of Science ®Google Scholar
• USMANI OS, MANEECHOTESU WAN K, ADCOCK IM, BARNES PJ: Glucocorticoid receptor activation following inhaled fluticasone and salmeterol. Am. I Respir. Crit. Care Med. (2002) 165(8):C57.
   Google Scholar
• CONFALONIERI M, MAINARDI E, DELLA PORTA R et al: Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax (1998) 53(7):583–585.
   PubMed Web of Science ®Google Scholar
• YILDIZ F, KAUR AC, ILGAZLI A et al: Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration (2000) 67(1):71–76.
   PubMed Web of Science ®Google Scholar
• •Supports the role of corticosteroids in reducing neutrophil-mediated Inflammatory responses in induced sputum in patients with COPD.
   Google Scholar
• BALBI B, MAJORI M, BERTACCO S et al.: Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest (2000) 117(6):1633–1637.
   PubMed Web of Science ®Google Scholar
• FUKAKUSA M, BERGERON C, TULIC MK et al.: Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-y-inducible protein 10 expression in asthmatic airway mucosa. I Allergy Clin. Immunol (2005) 115(2):280–286.
   PubMed Web of Science ®Google Scholar
• GIZYCKI MJ, HATTOTUWA KL, BARNES N, JEFFERY PK: Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax (2002) 57(9):799–803.
   PubMed Web of Science ®Google Scholar
• ••Double-blind, placebo-controlled,randomised trial of fluticasone propionate demonstrating a reduction in the numbers of biopsy mast cells associated with Improvement of symptoms.
   Google Scholar
• HATTOTUWA KL, GIZYCKI MJ, ANSARI TW, JEFFERY PK, BARNES NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. I Respic Crk Care Med. (2002) 165(12):1592–1596.
   PubMed Web of Science ®Google Scholar
• VERHOEVEN GT, HEGMANS JPJJ, MULDER PGH, HOOGSTEDEN HC, PRINS JB: Effect of an inhaled glucocorticosteroid, fluticasone propionate (FP) on inflammation in bronchial biopsies of COPD patients with bronchial hyperresponsiveness (BHR). Am. I Respic Grit. Care Med. (1999) 159:A524.
   Web of Science ®Google Scholar
• HOOGSTEDEN HC, VERHOEVEN GT, LAMBRECHT BN, PRINS JB: Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. Clin. Exp. Allergy (1999) 29\(Suppl. 2):116–124.
   Google Scholar
• ••Further significant evidence of the anti-inflammatory effects of fluticasone propionate in COPD.
   Google Scholar
• LLEWELLYN-JONES CG, HARRIS TA, STOCKLEY RA: Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am. Respir Grit. Care Med. (1996) 153(2):616–621.
   PubMed Web of Science ®Google Scholar
• ••Suggests a protective role for fluticasonepropionate through the reduction in the chemotactic activity, neutrophil recruitment and by affecting the proteinase/antiproteinase balance in the lung.
   Google Scholar
• VERHOEVEN GT, GARRELDS IM, HOOGSTEDEN HC, ZIJLSTRA FJ: Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Infiamm. (2001) 10(1):21–26.
   PubMed Web of Science ®Google Scholar
• SEETO LJ, BURGESS JK, JOHNSON PR: Effect of fluticasone and salmeterol on human alveolar macrophage cytokine production in patients with chronic obstructive pulmonary disease (COPD). Am. I Resp. Crit. Care Med. (2003) 167(7):A318.
   Google Scholar
• HOTCHKISS JA, HILASKI R, CHO H et al.: Fluticasone propionate attenuates ozone-induced rhinitis and mucous cell metaplasia in rat nasal airway epithelium. Am. I Respir Cell Mol Biol. (1998) 18(1):91–99.
   PubMed Web of Science ®Google Scholar
• BLYTH DI, PEDRICK MS, SAVAGE TJ et al: Induction, duration, and resolution of airway goblet cell hyperplasia in a murine model of atopic asthma: effect of concurrent infection with respiratory syncytial virus and response to dexamethasone. Am. J. Respir Cell Mol Biol. (1998) 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• BTS: BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 52\(Suppl. 5):S1–528.
   Google Scholar
• NIH: National Institutes of Health. Guidelines for the diagnosis and management of asthma, 1997, updated in 2002. (2002)
   Google Scholar
• PEDERSEN S, HANSEN OR: Budesonide treatment of moderate and severe asthma in children: a dose-response study. I Allergy Clin. Immunol (1995) 95(1 Part 1):29–33.
   Google Scholar
• MacKENZIE CA, WEINBERG EG, TABACHNIK E et al: A placebo controlled trial of fluticasone propionate in asthmatic children. Eur. I Pediatr. (1993) 152(10856–860.
   Google Scholar
• PAGGIARO PL, DAHLE R, BAKRAN I et al.: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351(9105):773–780.
   PubMed Web of Science ®Google Scholar
• •First large clinical trial investigating the efficacy and safety of ICS in COPD.
   Google Scholar
• BURGE PS, CALVERLEY PM, JONES PW et al: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. (2000) 320(7245):1297–1303.
   PubMed Web of Science ®Google Scholar
• ••Major clinical trial investigating the effectoff ICS on the rate of decline of FEVI and other clinical outcomes including rate of exacerbations in COPD.
   Google Scholar
• WEINER P, WEINER M, AZGAD Y, ZAMIR D: Inhaled budesonide therapy for patients with stable COPD. Chest (1995) 108(6):1568–1571.
   PubMed Web of Science ®Google Scholar
• WEINER P, WEINER M, RABNER M et al.: The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. J. Intern. Med. (1999) 245(1):83–89.
   PubMed Web of Science ®Google Scholar
• VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353(9167):1819–1823.
   PubMed Web of Science ®Google Scholar
• PAUWELS RA, LOFDAHL CG, LAITINEN LA et al: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl. Med. (1999) 340(25):1948–1953.
   Google Scholar
• ••Long-term clinical trial investigating the efficacy of inhaled corticosteroids in COPD.
   Google Scholar
• WOUTERS EFE: One year withdrawal offluticasone after three month treatment with combined fluticasone/salmeterol in COPD. Am. J. Resp. Grit. Care Med. (2004) 169(7):A519.
   Google Scholar
• LUNG HEALTH STUDY RESEARCH GROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. (2000) 343(26):1902–1909.
   PubMed Web of Science ®Google Scholar
• SIN DD, TU JV: Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. I Respir Grit. Care Med. (2001) 164(4):580–584.
   PubMed Web of Science ®Google Scholar
• SORIANO JB, KIRI VA, PRIDE NB, VESTBO J: Inhaled corticosteroids with/ without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am. I Respir Med. (2003) 2(1):67–74.
   PubMedGoogle Scholar
• VESTBO J: The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. (2004) 24(2):206–210.
   PubMed Web of Science ®Google Scholar
• KNOBIL K, WATKIN S, YATES J, DARKEN P, WIRE P: Fracture incidence from clinical trials of fluticasone propionate alone or in combination with salmeterol in the treatment of chronic obstructive pulmonary disease. Chest (2002)122 (Suppl. 4):43s.
   Google Scholar
• VAN STAA TP, LEUFKENS HG, COOPER C: Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. (2001) 16(3):581–588.
   PubMed Web of Science ®Google Scholar
• SUISSA S, BALTZAN M, KREMER R, ERNST P: Inhaled and nasal corticosteroid use and the risk of fracture. Am. I Respir Grit. Care Med. (2004) 169(1):83–88.
   PubMed Web of Science ®Google Scholar
• LEE TA, WEISS KB: Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. (2004)169(7):855–859.
   PubMed Web of Science ®Google Scholar
• SMEETH L, BOULIS M, HUBBARD R, FLETCHER AE: A population based case-control study of cataract and inhaled corticosteroids. Br. I. Ophthalmol (2003) 87(10):1247–1251.
   PubMed Web of Science ®Google Scholar
• CALVERLEY P, PAUWELS R, VESTBO J et al: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• ••Key clinical trial comparing benefits withICS-LABA combination treatment in COPD, with placebo and monotherapy.
   Google Scholar
• MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am. Respir Grit. Care Med. (2002) 166(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• HANANIA NA, DARKEN P, HORSTMAN D et al: The efficacy and 631 Expert Op/n. Investig. Drugs (2005) 14(5) safety of fluticasone propionate 250 jig! salmeterol 50 pg combined in the discus inhaler for the treatment of chronic obstrctive pulmonary disease. Chest (2003) 124:834–843.
   Google Scholar
• SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir J. (2003) 21(1):74–81.
   PubMed Web of Science ®Google Scholar
• CALVERLEY PM, BOONSAWAT W, CSEKE Z et al.: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 22(6):912–919.
   PubMed Web of Science ®Google Scholar
• GAMBLE E, GROOTENDORST DC, BRIGHTLING CE et al.: Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo6) in chronic obstructive pulmonary disease. Am. I Respir Grit. Care Med. (2003) 168(8):976–982.
   PubMed Web of Science ®Google Scholar
• GRUMELLI S, CORRY DB, SONG LZ et al.: An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. (2004) 1(1):E8.
   PubMed Web of Science ®Google Scholar